Market Pulse: U.S. stocks edged mixed Friday as tech wavered under fresh SpaceX warnings, while industrial staples held ground after WD-40’s blowout Q2 beat kept traders afloat.
Key Movers: WD-40’s surprise guidance boost, TCS’s Q1 shocker rallying skeptics, and a bearish Genesis Line flash in SpaceX shares drove Friday’s mood swings.
Macro & Politics: Starbucks’ plan to slash hundreds of millions via sovereign AI grabbed headlines just as Beijing green-lit big funding for wearable brain-computing, stoking policy chatter.
What’s Next: Watch industrial and consumer-staple earnings kicking off Monday, and track Fed speak for fresh tone on rates before markets open.
📈 Breaking Financial News
How Psychiatric Drugs Win Approval — and Why It Matters for Children
Researchers writing in JAMA Psychiatry argue that the FDA-approved label for Exxua, an antidepressant, highlights successful clinical trials while omitting numerous studies that failed to show the drug worked better than placebo. For parents, FDA approval can…
Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
– Vertex Pharmaceuticals (NasdaqGS:VRTX) received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle c…
Wendy’s Vs. McDonald’s: Buy Wendy’s to Ride the ‘Project Fresh’ Short-Squeeze Momentum and Avoid McDonald’s
Wendy's just posted a quarter where beating Wall Street estimates still meant losing customers fast, and yet the stock is surging while McDonald's quietly bl…
TCS shares close 1% higher after Q1 earnings beat; valuation zooms ₹7,706 cr
TCS shares rise 1% after strong Q1 earnings and optimistic demand outlook, boosting market valuation by ₹7,706 crore.
While Neuralink drills into skulls, China’s BrainCo is betting brain tech will be something you wear
The most visible race in brain-computer interfaces involves surgery. But one of China’s most valuable neurotech firms is deliberately not competing in it, CNBC reports. BrainCo, based in Hangzhou, builds devices that read the brain from outside the skull. Hea…
The Liquidity Engine Powering Crypto's Comeback
Institutional capital is flooding in while most investors remain completely unaware – creating what could be the buying opportunity of a lifetime. Exposed: Crypto's liquidity backbone set for massive gains – get all details for just $3!
🔍 Market Analysis & Insights
Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
Starbucks (SBUX) is building internal AI tools to replace Microsoft and IBM software, targeting $400 million in annual vendor spend and cutting $30 million f…
Ethereum Price Forecast: ETH Could Hit $2,400 If This Pattern Is Confirmed
Ethereum is showing signs of a potential bullish reversal as it retests the $1,800 resistance, a move that could confirm a double-bottom pattern and open a p…
MicroVision Shareholders Clear Reverse Split Plan, Convertible Note Share Issuance
Microvision (NASDAQ:MVIS) shareholders approved all five proposals presented at the company’s 2026 annual meeting, including the election of directors, autho…
SpaceX Stock’s ‘Genesis Line’ Is Screaming a Warning for Investors
What do recent closes below SpaceX's so-called “genesis line” mean for investors?
Prediction: Can Costco Stock Reach $2,000 by 2030?
Costco Wholesale (NASDAQ:COST) compounds like a growth stock while wearing a defensive jersey. Shares trade at $953.13, up 10.84% YTD, yet still 2.77% below…
Something doesn't add up
Jobs that “existed”… didn't in reality. The government deploying record AI spending. Yet Buffett holds $344B cash—his largest position EVER. Louis Navellier's grading system reveals what the Wall Street elite see but won't tell you.
💰 Investment Opportunities
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena administered via…
Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity
Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity – Journal of Clinical Research in Pediatric Endocrinology
Explosive Growth in Generative AI in Pharmaceuticals: Market Set to Reach $9.36 Billion by 2030 at 30.9% CAGR
Key opportunities in the generative AI pharmaceutical market include the rise of precision medicine, AI-driven drug design, virtual clinical trials, and biopharmaceutical simulation. The focus on personalized therapies and advancements in AI algorithms enhanc…
WD-40 Greases Wall Street’s Expectations With Blowout Q2 Beat
WD-40 stock jumped as much as 14.5% after Q2 revenue and EPS beat estimates, prompting the company to raise its full-year guidance.
BridgeBio stock jumps after rival heart drug fails key trial
A rival drug failure can sometimes move a biotech stock almost as much as a company’s own clinical data. That is what happened to BridgeBio on July 9. Bridge…
Unfiltered Market Commentary
What everyone’s missing is in Activistpost.com’s “How Psychiatric Drugs Win Approval — and Why It Matters for Children,” which shows the FDA label for Exxua touting wins while ghosting failures. That’s a damn oversight, not just marketing flair—any biotech investor should be wary of half-told stories driving big rerates.
Look at MarketBeat’s “Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs” against The Next Web’s “While Neuralink drills into skulls, China’s BrainCo is betting brain tech will be something you wear.” One’s an enterprise beast slashing costly vendor spend—$400 million a year—while the other bets on non-invasive neurotech. Few are connecting that split, but it’s shaping where capex and talent flow.
Actionable takeaway: load up on under-the-radar AI-centric industrial plays poised to benefit from in-house platforms, but steer clear of Reddit-fueled squeezes in casual dining. Focus on real catalysts, not hype loops, and you’ll be ahead when the tape rerates these sectors.